LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

Plus, news about ​​Opthea, Apollomics, LaunXP and AstraZeneca: LifeMine reduces headcount: The Boston biotech went through a “company-wide restructuring,” according to employees’ LinkedIn posts. The biotech last disclosed a $175 million Series ...